BioAlliance Pharma SA a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, announced that it has acquired the European commercial rights to ondansetron oral spray (OS) from NovaDel Pharma Inc.
The details can be read here.
No comments:
Post a Comment